
Discovery pinpoints new therapeutic target for atopic dermatitis
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility GuidelinesEurekAlert! is a service of the American Association for the Advancement of Science.
Researchers from Trinity College Dublin have discovered a key mechanism underlying bacterial skin colonisation in atopic dermatitis, which affects millions around the globe. By identifying a major mechanism through which Staphylococcus aureus binds to the skin of patients with AD the team has opened the possibility of targeting this pathway as a therapeutic option in AD.
Acta Pharmaceutica Sinica B Volume 10, Issue 12 Publishes The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
Acta Pharmaceutica Sinica B Volume 10, Issue 11 Publishes Special Issue: Tumor Microenvironment and Drug Delivery Guest Editors: Huile Gao, West China School of Pharmacy, Sichuan University, Chengdu, China; Zhiqing Pang, Fudan University, Shanghai, China and Wei He, China Pharmaceutical University, Nanjing, China
Researchers from the University of Sheffield found the osteoporosis drug, denosumab, could protect patients from osteolysis, reduce the need for re-operations, and reduce the health burden of this disease.
Currently there's no treatment for botulism once the toxin gets into neurons. This novel treatment neutralized the toxin with a second, modified botulinum toxin that delivered a mini antibody into the cells - reversing paralysis in mice.
Across the world, health care workers and high-risk groups are beginning to receive COVID-19 vaccines, offering hope for a return to normalcy amidst the pandemic. However, the vaccines authorized for emergency use in the U.S. require two doses to be effective, which can create problems with logistics and compliance. Now, researchers reporting in ACS Central Science have developed a nanoparticle vaccine that elicits a virus-neutralizing antibody response in mice after only a single dose.
POSTECH-UNIST joint research team finds ways to control the surface texture of nanostructures.
Until now, the reason why the drug levodopa (L-Dopa), which reduces the motor symptoms of Parkinson's disease, declines in efficacy after a few years' use has been unknown. A side effect that then often occur is involuntary movements. A Swedish-French collaboration, led from Uppsala University, has now been able to connect the problems with defective metabolism of L-Dopa in the brain. The study is published in Science Advances.
Researchers at the University of Gothenburg now suggest a possible cure for children with hard-to-treat forms of neuroblastoma using a new combination of drugs. In a new study in the journal Cancer Research, they describe how a two small molecule-based drug combination likely inhibit the tumor's growth.
By comparing thousands of bacterial genomes, scientists in Gothenburg, Sweden have traced back the evolutionary history of antibiotic resistance genes. In almost all cases where an origin could be determined, the gene started to spread from bacteria that, themselves, can cause disease.